<DOC>
	<DOCNO>NCT00675233</DOCNO>
	<brief_summary>RATIONALE : Photodynamic therapy use drug , HPPH , become active expose certain kind light . When drug active , tumor cell kill . This may effective treatment laryngeal cancer . PURPOSE : This phase I trial study side effect best dose laser light therapy give together HPPH treat patient dysplasia , cancer situ , invasive cancer larynx .</brief_summary>
	<brief_title>Photodynamic Therapy Using HPPH Treating Patients With Dysplasia , Cancer Situ , Invasive Cancer Larynx</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose laser light therapy use fix dose HPPH patient dysplasia , squamous cell carcinoma situ , T1 squamous cell carcinoma larynx . Secondary - To determine response patient treat regimen . OUTLINE : This dose-escalation study laser light therapy . Patients undergo photodynamic therapy comprise HPPH IV 1 hour day 1 laser light therapy tumor day 2 . Approximately 8 week later , patient partial response , response , geographical miss may receive second course treatment . After completion study treatment , patient follow 1 week , 1 month , 3 month , periodically thereafter .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsyconfirmed diagnosis 1 following : Mild severe dysplasia larynx Dysplastic lesion &gt; 3 mm thickness Squamous cell carcinoma situ larynx T1 squamous cell carcinoma larynx Tumor &gt; 3 mm thickness No T2T4 squamous cell carcinoma larynx Newly diagnose recurrent disease PATIENT CHARACTERISTICS : ECOG performance status 02 Total bilirubin &gt; 2.0 mg/dL Creatinine &gt; 2.0 mg/dL SGOT &gt; 3 time upper limit normal ( ULN ) Alkaline phosphatase &gt; 3 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 36 month completion study treatment No porphyria No hypersensitivity porphyrin porphyrinlike compound PRIOR CONCURRENT THERAPY : Any prior therapy allow At least 4 week since prior concurrent chemotherapy radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>stage I squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage 0 laryngeal cancer</keyword>
</DOC>